Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Roche’s Columvi passes Phase 3 lymphoma test as competition with AbbVie, Genmab continues

Roche’s Columvi is on the path to a full approval and potentially a label expansion in an earlier lymphoma setting after hitting the primary endpoint

April 16, 2024

Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this year

Seven months after Nimbus Therapeutics sold an experimental autoimmune disease medicine to Takeda Pharmaceuticals for up to $6 billion, the Boston biotech said Wednesday it has raised

September 6, 2023

Navigating the Murky Waters of Healthcare Billing

Ritwik Batabyal, Chief Technology and Innovation Officer at Mastek at Mastek The traditional fee-for-service healthcare model, which reimburses providers based solely on the quantity of

September 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.